We recently compiled a list of the 10 Most Promising Dividend Stocks According to Hedge Funds. In this article, we are going ...

LabConnect, a leading provider of central lab services and functional service provider solutions, is proud to announce the formation of its ...

We recently compiled a list of the 12 Best Big Name Stocks to Invest in Now. In this article, we are going to take a look at ...

We recently compiled a list of the 12 Best Long Term Low Risk Stocks to Buy Right Now. In this article, we are going to take ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other long term low risk stocks. As the DeepSeek craze ignites a sell-off in the tech ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best big name stocks to invest in now. Big name stocks refer to well-known companies ...

Truist Securities reaffirmed its Buy rating and $1,038.00 price target for Eli Lilly and Company (NYSE:LLY) shares, with analyst targets ranging from $580 to $1,190. The company, which has ...

I think Eli Lilly and Company's stock correction may be ending ... than-expected channel inventory at year-end.” So it doesn't really mean that their longer-term sales figures “will definitely ...

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in lower-than-expected revenue for the company's famous weight management drug ...

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50 ...

The Eli Lilly and Company-Bond has a maturity date of 6/1/2025 and offers a coupon of 7.1250%. The payment of the coupon will take place 2.0 times per biannual on the 01.12.. At the current price ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Eli Lilly (LLY ... buy or sell before they've reported. Lilly doesn't appear a compelling earnings-beat candidate.